Anti‐ENA antibody profiles in patients with hepatitis C virus infection

Litwin, Christine M.; Rourk, Angela R.

doi:10.1002/jcla.22279

Cited by 9 publications

(10 citation statements)

References 15 publications

(26 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ANA+ENA detection represents the measuring of a series of autoantibodies majorly antinuclear antibodies, which are closely related with many autoimmune diseases, and involved in the pathogenesis of many kinds of viruses 33,34 . Lately, Zhong et al revealed patients with autoimmune rheumatic disease might be more susceptible to COVID-19 infection than the general population 15 .…”

Section: Discussionmentioning

confidence: 99%

Antinuclear Autoimmunity Potentially Makes the Middle-aged and Female with COVID-19 Prone to Severe Progression: A Case-control Study

Cao

Zhou

Zhang

et al. 2021

Preprint

View full text Add to dashboard Cite

BackgroundElderliness is known risk factor for severe progression of COVID-19 due to compromised immunity, however aberrant hyperactive immune response including autoimmunity might be responsible for younger patients.Methods162 patients tested with autoimmunological detections were enrolled, and study of “Severe” cases and “Non-severe” controls was retrospectively analyzed. ResultsMultivariable analysis involving antinuclear autoimmunity manifests correlation of disease severity with middle age and attenuates the risk of age older than 65. Middle age (45≤age≤65) and female turn out to be the risk factors after hierarchical cluster analysis, before which however sex was not correlated. We find antinuclear autoimmunity to be strongly correlated with severity for the middle-aged (OR= 21.000, 95% CI 4.893- 90.126, p< 0.001) and female (OR= 16.044, 95% CI 4.717- 54.568, p< 0.001), especially for the middle-aged female (Pearson R= 0.770, p< 0.001). Incidence of symptoms fever and chest distress, and complication myocardial injury are statistically more frequent in patients with positive antinuclear antibody, compared with those negative. Severe patients with positive antinuclear antibody possess significantly shorter onset of symptoms to severity time (p= 0.021), indicating quicker progression, and interestingly, present more incidence (21%) of post-remission aggravation, compared with those negative (6%). ConclusionsThe presence of antinuclear autoimmunity potentially makes COVID-19 prone to severe progression, especially for the middle-aged and female, probably even quicker.

show abstract

Section: Discussionmentioning

confidence: 99%

Antinuclear Autoimmunity Potentially Makes the Middle-aged and Female with COVID-19 Prone to Severe Progression: A Case-control Study

Cao

Zhou

Zhang

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Despite the clinical associations of ANA with rheumatic and non-rheumatic conditions, the relationship between these antibodies and specific disease manifestations is often unknown since their targets are predominantly intracellular and ubiquitously expressed [ 57 ].…”

Section: Auto-antibodies and Hcvmentioning

confidence: 99%

Autoantibodies and Rheumatologic Manifestations in Hepatitis C Virus Infection

Priora¹,

Borrelli

Parisi

et al. 2021

Biology

View full text Add to dashboard Cite

HCV is a virus that can cause chronic infection which can result in a systemic disease that may include many rheumatologic manifestations such as arthritis, myalgia, sicca syndrome, cryoglobulinemia vasculitis as well as other non-rheumatological disorders (renal failure, onco-haematological malignancies). In this population, the high frequency of rheumatoid factor (45–70%), antinuclear (10–40%) and anticardiolipin (15–20%) antibodies is a B-cell mediated finding sustained by the infection. However, the possibility that a primitive rheumatic pathology may coexist with the HCV infection is not to be excluded thus complicating a differential diagnosis between primitive and HCV-related disorders.

show abstract

“…In conclusion, non-organ-specific humoral autoimmunity is significantly present in adult patients with 47,XXY, but not in patients with HGA. Because it is always clinically difficult to precisely diagnose a systemic autoimmune disease [22][23][24]31,33,35] and some autoimmune diseases, such as SLE, are more severe in these patients than in 46,XY men [37], the additional information from the presence of non-organ-specific autoantibodies is important, as it may strongly support the analysis of the clinical presentation and physical examination of each patient. As reported in the literature, the occurrence of these autoantibodies precedes the possible development and progression of most autoimmune disorders [47,48], which suggests the importance of screening non-organ-specific autoimmunity in Xchromosome aneuploidies in clinical practice to identify patients at risk of developing non-organ-specific autoimmune diseases.…”

Section: F I G U R Ementioning

confidence: 99%

“…These autoantibodies have high avidity and specificity and are widely used in the diagnosis and monitoring of SLE [30][31][32]. ENAs represent a large family of non-organ-and non-species-specific autoantibodies, the detection of which is of great importance in the laboratory diagnosis of systemic rheumatic autoimmune diseases [33][34][35][36].…”

Section: Introductionmentioning

confidence: 99%

Non-organ-specific autoimmunity in adult 47,XXY Klinefelter patients and higher-grade X-chromosome aneuploidies

Panimolle

Tiberti

Spaziani

et al. 2021

Clinical and Experimental Immunology

View full text Add to dashboard Cite

Current literature regarding systemic autoimmune diseases in X-chromosome aneuploidies is scarce and limited to case reports. Our aim was to evaluate the frequency of anti-nuclear (ANAs), extractable nuclear (ENA), anti-double-stranded DNA (dsDNAs), anti-smooth muscle (ASMAs) and anti-mitochondrial (AMAs) antibodies in a large cohort of adults with Klinefelter's syndrome (KS, 47,XXY) and rare higher-grade sex chromosome aneuploidies (HGAs) for the first time. Sera from 138 X-chromosome aneuploid patients [124 adult patients with 47,XXY KS and 14 patients with HGA (six children, eight adults)] and 50 age-matched 46,XY controls were recruited from the Sapienza University of Rome (2007-17) and tested for ANAs, ENAs, anti-dsDNAs, ASMAs and AMAs. Non-organ-specific immunoreactivity was found to be significantly higher in patients with 47,XXY KS (14%) than in the controls (2%, p = 0.002). Among all the antibodies investigated, only ANAs were observed significantly more frequently in patients with 47,XXY KS (12.1%) than in the controls (2%, p = 0.004). No anti-dsDNA immunoreactivity was found. Stratifying by testosterone replacement therapy (TRT), non-organ-specific autoantibody frequencies were higher in TRT-naive (p = 0.01) and TRT-treated groups than in controls. No patients with HGA were found positive for the various autoantibodies. Non-organ-specific autoantibodies were significantly present in 47,XXY adult patients. Conversely, HGAs did not appear to be target of non-organspecific immunoreactivity, suggesting that KS and HGAs should be considered as two distinct conditions. The classification and diagnosis of systemic autoimmune diseases is frequently difficult. To support a correct clinical evaluation of KS disease and to prevent eventual secondary irreversible immune-mediated damages, we highlight the importance of screening for non-organ-specific autoimmunity in Klinefelter's syndrome.

show abstract

Anti‐ENA antibody profiles in patients with hepatitis C virus infection

Cited by 9 publications

References 15 publications

Antinuclear Autoimmunity Potentially Makes the Middle-aged and Female with COVID-19 Prone to Severe Progression: A Case-control Study

Antinuclear Autoimmunity Potentially Makes the Middle-aged and Female with COVID-19 Prone to Severe Progression: A Case-control Study

Autoantibodies and Rheumatologic Manifestations in Hepatitis C Virus Infection

Non-organ-specific autoimmunity in adult 47,XXY Klinefelter patients and higher-grade X-chromosome aneuploidies

Contact Info

Product

Resources

About